title: New once-daily, highly effective rescue triple therapy after multiple Helicobacter pylori treatment failures: a pilot study.
abstract: BACKGROUND
  Helicobacter pylori treatment failure is a growing problem in daily practice.
  
  
  OBJECTIVE
  To determine the efficacy of the combination of rabeprazole, levofloxacin and furazolidone as a rescue therapy.
  
  
  METHODS
  Duodenal ulcer patients previously submitted, without success, to at least two H. pylori treatment regimens were included. Gastroscopy (urease test, histological examination and culture) and (13)C-urea breath test were performed. All patients received a combination of rabeprazole 20 mg, levofloxacin 500 mg and furazolidone 200 mg (two tablets) administered in a single dose in the morning for 10 days. Clinical examination and a new (13)C-urea breath test were performed 90 days after therapy.
  
  
  RESULTS
  Twelve patients (eight females and four males), mean age 43 (30-58) years were included. Two patients failed to complete the treatment because of nausea and vomiting. Ten patients completed the study and took all the medications as advised. Culture was obtained in six patients: 100 and 83% of the samples were sensitive to furazolidone and levofloxacin, respectively. Per-protocol and intention-to-treat eradication rates were 100 and 83% (P = 0.019).
  
  
  CONCLUSIONS
  the combination of rabeprazole, levofloxacin and furazolidone in a single daily dose for 10 days constitutes a highly-effective and low-cost alternative as a third-line therapy in patients infected with H. pylori.
authors.affiliation: Instituto Alfa de Gastroenterologia, Universidade Federal Minas Gerais, Belo Horizonte, Minas Gerais, Brazil. lcoelho@gold.com.br
authors.forename: L G V
authors.initials: LG
authors.lastname: Coelho
authors.forename: L D
authors.initials: LD
authors.lastname: Moretzsohn
authors.forename: W L S
authors.initials: WL
authors.lastname: Vieira
authors.forename: M A
authors.initials: MA
authors.lastname: Gallo
authors.forename: M C F
authors.initials: MC
authors.lastname: Passos
authors.forename: J M
authors.initials: JM
authors.lastname: Cindr
authors.forename: M C
authors.initials: MC
authors.lastname: Cerqueira
authors.forename: L
authors.initials: L
authors.lastname: Vitiello
authors.forename: M L
authors.initials: ML
authors.lastname: Ribeiro
authors.forename: S
authors.initials: S
authors.lastname: Mendonça
authors.forename: J
authors.initials: J
authors.lastname: Pedrazzoli-Júnior
authors.forename: L P
authors.initials: LP
authors.lastname: Castro
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D000891:Anti-Infective Agents, Local / Q000008:administration & dosage*; D000897:Anti-Ulcer Agents / Q000008:administration & dosage*; D001562:Benzimidazoles / Q000008:administration & dosage; D004338:Drug Combinations; D005260:Female; D005664:Furazolidone / Q000008:administration & dosage; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D064704:Levofloxacin; D008297:Male; D008875:Middle Aged; D015242:Ofloxacin / Q000008:administration & dosage; D009853:Omeprazole / Q000008:administration & dosage / Q000031:analogs & derivatives*; D010865:Pilot Projects; D064750:Rabeprazole; D016896:Treatment Outcome
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000900:Anti-Bacterial Agents; D000891:Anti-Infective Agents, Local; D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; D004338:Drug Combinations; D064750:Rabeprazole; D005664:Furazolidone; D064704:Levofloxacin; D015242:Ofloxacin; D009853:Omeprazole